In this study, we chose to design and evaluate the efficacy of short-peptides specifically targeted against FJX1, a tumor antigen that we have previously observed to be highly elevated in NPC, but low in normal nasopharyngeal tissue (Figures A and B in S3 File). The gene discussed is FJX1; the disease is nasopharyngeal carcinoma.